Related Experiment Videos
SL65.0472 blocks 5-hydroxytryptamine-induced vasoconstriction in a dog hindlimb ischemia model
Fabrice Barbe1, Etienne Gautier, Jean-Pierre Bidouard
1Sanofi-Synthélabo Research, Cardiovascular Thrombosis Research Department, 1 Avenue Pierre Brossolette, 91380 Chilly-Mazarin, France.
European Journal of Pharmacology
|August 12, 2003
Summary
SL65.0472 effectively blocks vasoconstriction caused by serotonin (5-HT) and sumatriptan in canine hindlimb ischemia. This 5-hydroxytryptamine (5-HT) receptor antagonist shows promise in managing blood flow during ischemic events.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Ischemia Studies
Background:
- 5-hydroxytryptamine (5-HT) plays a role in vasoconstriction, particularly during ischemic conditions.
- Sumatriptan, a 5-HT agonist, can also induce vasoconstriction.
- Understanding antagonists for these receptors is crucial for managing circulatory issues.
Purpose of the Study:
- To evaluate the efficacy of SL65.0472 as a 5-HT1B/5-HT2A receptor antagonist.
- To assess its ability to inhibit 5-HT and sumatriptan-induced vasoconstriction in a canine hindlimb ischemia model.
Main Methods:
- A canine model of hindlimb ischemia was established via arterial ligation and excision.
- Blood flow was measured following intra-aortic injections of 5-HT and sumatriptan.
- The effects of SL65.0472 and ketanserin on vasoconstriction were compared.
Main Results:
- Intra-aortic 5-HT significantly reduced blood flow in the ischemic hindlimb.
- SL65.0472 administration markedly inhibited 5-HT-induced vasoconstriction (-66%).
- SL65.0472 also effectively blocked sumatriptan-induced vasoconstriction in both ischemic and normal hindlimbs.
Conclusions:
- SL65.0472 is a potent antagonist of 5-HT receptor-mediated vasoconstriction.
- The compound demonstrates effectiveness against both 5-HT and sumatriptan-induced vasoconstriction.
- SL65.0472 shows potential therapeutic value in managing vasoconstriction associated with ischemia.